NYSE:OCX
OncoCyte Corp Stock News
$2.48
+0.0400 (+1.64%)
At Close: Apr 26, 2024
OncoCyte (OCX) Reports Q4 Loss, Misses Revenue Estimates
06:11pm, Tuesday, 16'th Mar 2021
OncoCyte (OCX) delivered earnings and revenue surprises of 10.00% and -52.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results
04:01pm, Tuesday, 16'th Mar 2021
DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020
Oncocyte Announces Formation of Medical Advisory Board
08:00am, Tuesday, 09'th Mar 2021
Key Opinion Leaders in Oncology and Immune-Oncology Will Help Advance Development of Company's Diagnostic and Monitoring Tests Key Opinion Leaders in Oncology and Immune-Oncology Will Help Advance Dev
Oncocyte to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16
04:01pm, Wednesday, 03'rd Mar 2021
IRVINE, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points a
Oncocyte to Begin Trading on the Nasdaq Stock Market on March 8, 2021
04:05pm, Tuesday, 23'rd Feb 2021
IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac
Oncocyte to Participate in Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
04:05pm, Tuesday, 16'th Feb 2021
IRVINE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac
Oncocyte Announces Closing of $40 Million Public Offering of Common Stock
04:05pm, Tuesday, 09'th Feb 2021
IRVINE, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac
Why Oncocyte Shot 13% Higher Today
06:06pm, Friday, 05'th Feb 2021
The announcement of a new share issue usually drives a stock's price down, after all.
Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock
08:25am, Friday, 05'th Feb 2021
IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac
Oncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc.
08:00am, Tuesday, 02'nd Feb 2021
Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing
Oncocyte Announces $25 Million Registered Offering
04:08pm, Wednesday, 20'th Jan 2021
Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings
Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference
06:21pm, Tuesday, 12'th Jan 2021
IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ac
10 Best Stocks For 2021: After An Unprecedented Year, What's Next?
02:07pm, Thursday, 07'th Jan 2021
Which of our experts will win the best stocks contest? They're all betting on themes likely to dominate in 2021 and beyond.
Best Stocks for 2021: OncoCyte (OCX)
03:46pm, Tuesday, 29'th Dec 2020
One of the top stocks to buy for 2021 is OncoCyte, a molecular diagnostics company that offers genetic testing to physicians and patients. The post Best Stocks for 2021: OncoCyte (OCX) appeared first
Do Options Traders Know Something About OncoCyte (OCX) Stock We Don't?
09:47am, Thursday, 17'th Dec 2020
Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.
